Afatinib (Giotrif®) : The 1st choice in 1st-line

Afatinib: The 1st line choice in sequential therapy of NSCLC

 
 

Higher in-vitro sensitivity of common EGFR mutations to AFATINIB translates to improved tumor responses in NSCLC

Document ID: PC-VN-101464

28/06/2021

Author: Boehringer Ingelheim

123,000
Views

100k 340

NHỮNG NỘI DUNG LIÊN QUAN

 
PC-VN-101464
Production date: June 2021